Chris Chinn is an experienced leader in Real World Evidence (RWE) and health economics, currently serving as the Head of Neurology for RWE at UCB since March 2021. Between September 2015 and February 2021, Chris held the position of Vice President and Leader of HEOR for China and Emerging Markets at Sanofi, overseeing evidence strategies to meet access goals. Prior roles include Vice President at GSK, where Chris led global RWE and health investment evidence strategies, and Senior Director at Eli, managing European outcomes research. Chris's career began as a Finance Manager at SmithKline Beecham Corporation, followed by roles in health economics. Educational qualifications include a BA in Biochemistry from the University of Oxford and an MSc in Economics and Quantitative Methods from City University.
This person is not in any teams
This person is not in any offices